GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Gross Profit

Traws Pharma (Traws Pharma) Gross Profit : $0.23 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Gross Profit?

Traws Pharma's gross profit for the three months ended in Dec. 2023 was $0.06 Mil. Traws Pharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.23 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Traws Pharma's gross profit for the three months ended in Dec. 2023 was $0.06 Mil. Traws Pharma's Revenue for the three months ended in Dec. 2023 was $0.06 Mil. Therefore, Traws Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Traws Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Traws Pharma Gross Profit Historical Data

The historical data trend for Traws Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Gross Profit Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 0.23 0.23 0.23 0.23

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.06 0.06

Competitive Comparison of Traws Pharma's Gross Profit

For the Biotechnology subindustry, Traws Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Gross Profit falls into.



Traws Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Traws Pharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.226 - 0
=0.23

Traws Pharma's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.056 - 0
=0.06

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Traws Pharma's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.06 / 0.056
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Traws Pharma  (NAS:TRAW) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Traws Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Traws Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (Traws Pharma) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

Traws Pharma (Traws Pharma) Headlines